Review: Insulin-like growth factor-related proteins and diabetic complications

Abstract

The insulin-like growth factor system and, in particular, insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-1 (IGFBP-1) are dysregulated in type 1 and type 2 diabetes. Serum IGF-I levels are low in both forms of diabetes, and this may be in part genetically determined. It is possible that the reduced serum levels of IGF-I are involved in the development of microvascular and macrovascular complications. Fasting serum IGFBP-1 levels are usually low in early type 2 diabetic patients with insulin resistance and hyperinsulinaemia but may be raised in patients with particularly poor glycaemic control and severe beta-cell failure. Treatment with IGF-I/binding protein complexes has been shown to improve glycaemic control in conjunction with insulin and may in future have a place in the treatment of diabetes, potentially to prevent diabetic complications. Serum IGFBP-1 determination may have utility in the assessment of cardiovascular risk and as an indicator for insulin resistance.

Keywords

insulin-like growth factor insulin-like growth factor binding protein diabetes microvascular disease macrovascular disease.

Get full access to this article

View all access options for this article.

References

Froesch ER , Hussain MA , Schmid C. , Zapf J. Insulin-like growth factor-I: physiology, metabolic effects and clinical uses . Diab Metab Rev 1996;12: 195-215.

Binoux M. The IGF system in metabolism regulation. Diab Metab 1995; 21:330-7.

Monzavi R. , Cohen P. IGFs and IGFBPs: role in health and disease. Best Pract Clin Endocrinol Metab 2002;16:433-47.

Boisclair YR , Rhoads RP , Ueki I. , Wang J. , Ooi GT The acid labile subunit (ALS) of the 150KDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170: 63-70.

Collett-Solberg PF , Cohen P. The role of insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996;25:591-614.

Feldmann B. , Jehle PM , Mohan S. et al. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF binding proteins. Growth Horm IGF Res 2000;10:53-9.

Heald AH , Cruickshank JK , Riste LK et al. Close relation of fasting insulinlike growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001;44:333-9.

Holt RIG , Simpson HL , Sonksen PH The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diab Med 2003; 20:3-15.

Garay-Sevilla ME , Nava LE , Malacara JM , Wrobel K. , Perez U. Advanced glycosylation end products, insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) in patients with type-2 diabetes mellitus. Diab Metab Res Rev 2000;16:106-13.

10.

Bang P. , Nygren J. , Carlsson-Skwirut C. , Thorell A. , Ljungqvist O. Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab 1998;83:2509-15.

11.

Clauson PG , Brismar K. , Hall K. , Linnarsson R. , Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type-2 diabetic patients in Sweden . Scand J Clin Lab Invest 1998;58:353-60.

12.

Chantelau E. , Kohner EM Why some cases of retinopathy worsen when diabetic control improves. BMJ 1997;315:1105-06.

13.

Henricsson M. , Berntorp K. , Fernlund P. , Sundkvist G. Progression of retinopathy in insulin-treated type-2 diabetic patients. Diabetes Care 2002 ;25:381-5.

14.

Giannini S. , Cresci B. , Manuelli C. et al. Insulin-like growth factor binding protein production in bovine retinal endothelial cells . Metabolism 1997; 46:1367-79.

15.

Janssen Jamjl , Lamberts SWJ. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol 2000;52:1-9.

16.

Simo R. , Lecube A. , Segura RM , Garcia-Arumi J. , Hernandez C. Free insulin like growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy . Am J Ophthalmol 2002;134:376-82.

17.

Simo R. , Hernandez C. , Segura RM et al. Free insulin-like growth factor-I in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case control study. Clin Sci 2003;104:223-30.

18.

Gibson JM , Westwood M. , Lauszus FF , Klebe JG , Flyvbjerg A. , White A. Phosphorylated insulin-like growth factor binding protein-1 is increased in pregnant diabetic subjects. Diabetes 1999 ;48:321-6.

19.

Jones JI , D' Ercole AJ , Camacho-Hubner C. , Clemmons DR Phosphorylation of insulin-like growth factor (IGF)-binding protein-1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA 1991;88:7481-5.

20.

Chiarelli F. , Santilli F. , Mohn A. Role of growth factors in the development of diabetic complications. Horm Res 2000;53:53-67.

21.

Crosby SR , Tsigos C. , Anderton CD , Gordon C. , Young RJ , White A. Elevated plasma insulin-like growth factor binding protein-1 levels in type-1 (insulin-dependent) diabetic patients with peripheral neuropathy . Diabetologia 1992;35:868-72.

22.

Grandis M. , Nobbio L. , Abbruzzese M. et al. Insulin treatment enhances expression of IGF-I in sural nerves from diabetic patients. Muscle Nerve 2001;24:622-9.

23.

Russell JW , Feldman EL Insulin-like growth factor-I IGF-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm Metab Res 1999 ;31:90-6.

24.

Zhuang HX , Snyder CK , Pu SF , Ishii DN Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Experimental Neurology 1996;140:198-205.

25.

Brand FN , Kannel WB , Evans J. , Larson MG , Wolf PA Glucose intolerance, physical signs of peripheral artery disease and the risk of cardiovascular events: The Framingham study. Am Heart J 1998;136:919-27.

26.

Miettinen H. , Lehto S. , Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:6-75.

27.

Hayden JM , Reaven PD Cardiovascular disease in diabetes mellitus type-2: a potential role for novel cardiovascular risk factors. Curr Op Lipidol 2000;11:519-28.

28.

Lee WL , Chen JW , Ting CT , Wang PH Changes of the insulin-like growth factor-I system during acute myocardial infarction: implications on left ventricular remodelling. J Clin Endocrinol Metab 1999;84:1575-81.

29.

Izhar U. , Hasdai D. , Richardson DM , Cohen P. , Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis 2000;11:69-76.

30.

Montani A. , Forster L. , Tull S. , Angaard EE , Ferns GAA. Insulin-like growth factor-I modulates monocyte adhesion to EAhy 926 endothelial cells. Int J Exp Path 1996;77:31-5.

31.

Zenobi PD , Holzmann P. , Glatz Y. , Riesen WF , Froesch ER Improvement of lipid profile in type-2 (non-insulin dependent) diabetes mellitus by insulin-like growth factor-I. Diabetologia 1993;36:465-9.

32.

Vaessen N. , Heutink P. , Janssen JA et al. A polymorphism in the gene for IGF-I: functional properties and risk for type-2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.

33.

Janssen Jamjl , Lamberts SWJ.

The role of IGF-I in the development of cardiovascular disease in type-2 diabetes mellitus: is prevention possible?

Eur J Endocrinol 2002;146:467-77.

34.

Rietveld I. , Janssen JA , Hofman A. , Pols HA , van Duijn CM , Lambert SW A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol 2003;148:171-5.

35.

Frayling TM , Hattersley AT , McCarthy AM et al. A putative functional polymorphism in the IGF-I gene. Association studies with type-2 diabetes, adult height, glucose tolerance and fetal growth in UK populations. Diabetes 2002;51:2313-16.

36.

Heald AH , Siddals KW , Fraser W. et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type-2 diabetes. Diabetes 2002;51:2629-36.

37.

Zarich SW , Nesto RW Diabetic cardiomyopathy. Am Heart J 1989;118: 1000-12.

38.

Osterziel KJ , Rank MB , Strohm O. , Dietz R. The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-I and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol 2000;53:61-8.

39.

Norby FL , Wold LE , Duan J. , Hintz KK , Ren J. IGF-I attenuates diabetesinduced cardiac dysfunction in ventricular myocytes . Am J Physiol Endocrinol Metab 2002 ;238:E658-E666.

40.

Gibson JM , Westwood M. , Young RJ et al. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996;81:860-3.

41.

Heald AH , Cruickshank JK , Riste LK et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001;44:333-9.

42.

Hellenius MB , Brismar KE , Berglund BH et al. Effects on glucose tolerance, insulin secretion, insulin-like growth factor-I and its binding protein, IGFBP-1 in a randomised controlled diet and exercise study in healthy middle aged men . J Int Med 1995;238:121-30.

43.

Lemne C. , Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome: a study in borderline hypertension. Blood Press 1998;7:89-95.

44.

Saitoh H. , Kamoda T. , Nakahara S. et al. Insulin-like growth factor binding protein-1 as a predictor of glucose stimulated hyperinsulinaemia in pre-pubertal obese children. Eur J Endocrinol 1999;140:231-4.

45.

Leinonen ES , Salonen JT , Salonen RM et al. Reduced IGFBP-1 is associated with thickening of the carotid wall in type-2 diabetes. Diabetes Care 2002;25:1807-12.

46.

Clark RG , Mortensen DL , Reifsynder D. , Mohler M. , Etcheverry T. , Mukku V. Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycaemic and growth promoting activities of rhIGF-I in the rat. Growth Regul 1993:3:50-2.

47.

Clark RG , Mortensen DL , Carlsson LM , Carlsson B. , Carmignac D. , Robinson IC The obese growth hormone (GH)-deficient dwarf rat: boy responses to patterned delivery of GH and insulin-like growth factor-I. Endocrinology 1996;137:1904-12.

48.

Carroll PV , Umpleby M. , Ward GS et al. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion and improves the lipid profile in adults with IDDM . Diabetes 1997;46:1453-8.

49.

9. Cheetham TD , Connors M. , Clayton K. , Watts A. , Dunger DB The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor (rhIGF-I). Clin Endo 1997;46:415-24.

50.

Thrailkill KM Insulin-like growth factor-I in diabetes mellitus: its physiological metabolic effects and potential clinical utility. Diab Technol Ther 2000;2:69-80.

51.

Quattrin T. , Thrailkill K. , Baker L. et al. Improvement of HbA1c without increased hypoglycaemia in adolescents and young adults with type-1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin/ rhIGF-I in IDDM study group. J Pediatr Endocrinol Metab 2001;14:267-77.

52.

Thrailkill KM , Quattrin T. , Baker L. et al. Cotherapy with recombinant human insulin-like growth factor-I and insulin improves glycaemic control in type-1 diabetes . Diabetes Care 1999;22:585-92.

53.

Clemmons DR , Moses AC , McKay MJ , Sommer A. , Rosen DM , Ruckle J. The combination of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type-1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000;85:1518-24.

54.

Cusi K. , DeFronzo R. Recombinant human insulin-like growth factor-I treatment improves metabolic control in type-2 diabetes by ameliorating hepatic and muscle insulin resistance . J Clin Endocrinol Metab 2000;85: 3077-84.

55.

Moses AC , Young SCJ , Morrow LA , O'Brien M. , Clemmons DR Recombinant human IGF-I increases insulin sensitivity and improves glycaemic control in insulin requiring type-2 diabetes. Diabetes 1996;45: 91-100.

56.

O'Connell T. , Clemmons DR IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 2002;87:4356-60.